These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 25159076)
1. Phosphodiesterases as therapeutic targets for Huntington's disease. Fusco FR; Giampà C Curr Pharm Des; 2015; 21(3):365-77. PubMed ID: 25159076 [TBL] [Abstract][Full Text] [Related]
2. Role of Phosphodiesterases in Huntington's Disease. Fusco FR; Paldino E Adv Neurobiol; 2017; 17():285-304. PubMed ID: 28956337 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease. Cardinale A; Fusco FR CNS Neurosci Ther; 2018 Apr; 24(4):319-328. PubMed ID: 29500937 [TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease. Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. Giampà C; Laurenti D; Anzilotti S; Bernardi G; Menniti FS; Fusco FR PLoS One; 2010 Oct; 5(10):e13417. PubMed ID: 20976216 [TBL] [Abstract][Full Text] [Related]
6. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model. Giralt A; Saavedra A; Carretón O; Arumí H; Tyebji S; Alberch J; Pérez-Navarro E Hippocampus; 2013 Aug; 23(8):684-95. PubMed ID: 23576401 [TBL] [Abstract][Full Text] [Related]
7. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease. Nithianantharajah J; Hannan AJ Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949 [TBL] [Abstract][Full Text] [Related]
17. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease. Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248 [TBL] [Abstract][Full Text] [Related]
18. Huntington's Disease: Relationship Between Phenotype and Genotype. Sun YM; Zhang YB; Wu ZY Mol Neurobiol; 2017 Jan; 54(1):342-348. PubMed ID: 26742514 [TBL] [Abstract][Full Text] [Related]
19. Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases. Li Q; Liao Q; Qi S; Huang H; He S; Lyu W; Liang J; Qin H; Cheng Z; Yu F; Dong X; Wang Z; Han L; Han Y Eur J Med Chem; 2024 May; 271():116386. PubMed ID: 38614063 [TBL] [Abstract][Full Text] [Related]